Healthcare / BiotechnologyNasdaqGS
$2.15
-0.02 (-0.92%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-201.0M · quality 53.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
26/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$742M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-65.3%
↓Gross Margin
N/A
•Debt/Equity
0.28
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2018–2025 · 7 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.78x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-190.9M · FCF $-149.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | — | — | $22000.00 | $95000.00 | $156000.00 | $114.1M | $0.00 | $0.00 | — |
| Net Income | $-190.9M | $-190.9M | $-257.6M | $-327.3M | $-340.4M | $-182.1M | $-316.4M | $-184.6M | $-211.5M |
| EBITDA | $-177.5M | $-177.5M | $-243.3M | $-313.1M | $-321.2M | $-169.7M | $-250.8M | $-197.4M | $-191.8M |
| EPS | — | — | -1.32 | -2.09 | -2.32 | -1.34 | -2.63 | -1.83 | — |
| Operating Margin | — | — | -1170372.7% | -331044.2% | -215087.2% | -157.9% | — | — | — |
| Net Margin | — | — | -1170863.6% | -344489.5% | -218214.1% | -159.6% | — | — | — |
| Balance Sheet | |||||||||
| Debt/Equity | 0.28 | 0.28 | 0.21 | 0.19 | 0.15 | — | — | — | — |
| Current Ratio | 9.65 | 9.65 | — | — | — | — | — | — | — |
| Cash Flow | |||||||||
| Free Cash Flow | $-149.6M | $-149.6M | $-201.0M | $-239.2M | $-225.7M | $-206.3M | $-181.1M | $-188.1M | $-47.9M |
| Returns | |||||||||
| ROE | -65.3% | -65.3% | -61.0% | -63.9% | -51.0% | -19.7% | -31.2% | -29.3% | -30.1% |
| Valuation | |||||||||
| P/B | 1.69 | 1.69 | 1.00 | 0.89 | 1.31 | — | — | — | — |
| Growth & Yield | |||||||||
| Revenue Growth | — | — | -76.8% | -39.1% | — | — | — | — | — |
| EPS Growth | — | — | 36.8% | 9.9% | — | 49.0% | -43.7% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+83.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.32 → n/d
Residual
+83.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.